[1] Zhan Q, Qi X, Weng R, et al. Alterations of the human gut microbiota in intrahepatic cholestasis of pregnancy[J]. Front Cell Infect Microbiol, 2021, 11: 635680.
[2] Tang B, Tang L, Li S, et al. Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy[J]. Nat Commun, 2023, 14(1):1305.
[3] Fang D, Fang Y, Zhang W, et al. Comprehensive analysis of quantitative proteomics with DIA mass spectrometry and ceRNA network in intrahepatic cholestasis of pregnancy[J]. Front Cell Dev Biol, 2022, 10:854425.
[4] Shan D, Dong R, Hu Y. Current understanding of autophagy in intrahepatic cholestasis of pregnancy[J]. Placenta, 2021, 115:53-59.
[5] Beuers U, Wolters F, Oude Elferink R P J. Mechanisms of pruritus in cholestasis: understanding and treating the itch[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(1):26-36.
[6] Kremer A E, Martens J J, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus[J]. Gastroenterology, 2010, 139(3):1008-1018, 1018.e1.
[7] Yu H, Wangensteen K, Deng T, et al. MRGPRX4 in cholestatic pruritus[J]. Semin Liver Dis, 2021, 41(3):358-367.
[8] Mor M, Shmueli A, Krispin E, et al. Intrahepatic cholestasis of pregnancy as a risk factor for preeclampsia[J]. Arch Gynecol Obstet, 2020, 301(3):655-664.
[9] Perino A, Demagny H, Velazquez-Villegas L, et al. Molecular physiology of bile acid signaling in health, disease, and aging[J]. Physiol Rev, 2021, 101(2):683-731.
[10] De Vivo A, Baviera G, Giordano D, et al. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia[J]. Acta Obstet Gynecol Scand, 2008, 87:837-842.
[11] Li H, Gu B, Zhang Y, et al. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta[J]. Placenta, 2005, 26:210-217.
[12] Perez M J, Briz O. Bile-acid-induced cell injury and protection[J]. World J Gastroenterol, 2009,15(14): 1677-1689.
[13] Zhang L, Tang C, Ye C, et al. Intrahepatic cholestasis of pregnancy can increase the risk of metabolic disorders: a meta-analysis[J]. J Med Biochem, 2022, 41(4):549-558.
[14] Mashburn S, Schleckman E, Cackovic P, et al. Intrahepatic cholestasis of pregnancy: risk factors for severe disease[J]. J Matern Fetal Neonatal Med, 2022, 35(25):8566-8570.
[15] Fiorucci S, Mencarelli A, Palladino G, et al. Bile-acidactivated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders[J]. Trends Pharmacol Sci, 2009, 30:570-580.
[16] Martineau M G, Raker C, Dixon P H, et al. The metabolic profile of intrahepatic cholestasis of pregnancy is associated with impaired glucose tolerance, dyslipidemia, and increased fetal growth[J]. Diabetes Care, 2015, 38:243-248.
[17] Bellafante E, McIlvride S, Nikolova V, et al. Maternal glucose homeostasis is impaired in mouse models of gestational cholestasis[J]. Sci Rep, 2020, 10(1):11523.
[18] Marschall H U, Wikstrom Shemer E, Ludvigsson J F, et al. Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study[J]. Hepatology, 2013, 58(4): 1385-1391.
[19] Wikström Shemer E A, Stephansson O, Thuresson M, et al. Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovas-cular diseases: a population-based cohort study[J]. J Hepatol, 2015, 63(2):456-461.
[20] Geenes V, Chappell L C, Seed P T, et al. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study[J]. Hepatology, 2014, 59: 1482-1491.
[21] Arthuis C, Diguisto C, Lorphelin H, et al. Perinatal outcomes of intrahepatic cholestasis during pregnancy: an 8-year case-control study[J]. PLoS One, 2020, 15(2):e0228213.
[22] Sarker M, Zamudio A R, DeBolt C, et al. Beyond stillbirth: association of intrahepatic cholestasis of pregnancy severity and adverse outcomes[J]. Am J Obstet Gynecol, 2022, 227(3): 517.e1-517.e7.
[23] Ovadia C, Seed P T, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahe-patic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses[J]. Lancet, 2019, 393(10174):899-909.
[24] Herraez E, Lozano E, Poli E, et al. Role of macrophages in bile acid-induced inflammatory response of fetal lung during maternal cholestasis[J]. J Mol Med (Berl), 2014, 92:359-372.
[25] Perez M J, Macias R I, Duran C, et al. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid[J]. J Hepatol, 2005,43:324-332.
[26] Šimják P,Parízek A,Vítek L,et al.Fetal complications due to intrahepatic cholestasis of pregnancy[J]. J Perinat Med, 2015, 43(2):133-139.
[27] Vasavan T, Deepak S, Jayawardane I A, et al. Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations[J]. J Hepatol, 2021, 74:1087-1096.
[28] Smith D D, Rood K M, Rood K M. Intrahepatic cholestasis of pregnancy[J]. Clin Obstet Gynecol, 2020,63(1):134-151.
[29] Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy[J]. World J Gastroenterol, 2009, 15(17): 2049-2066.
[30] Zecca E, Costa S, Lauriola V, et al. Bile acid pneumonia: a "new" form of neonatal respiratory distress syndrome?[J]. Pediatrics, 2004, 114:269-272.
[31] Walker I A, Nelson-Piercy C, Williamson C. Role of bile acid measurement in pregnancy[J]. Ann Clin Biochem, 2002, 39:105-113.
[32] Shao Y, Chen S, Li H, et al. Maternal bile acid profile and subtype analysis of intrahepatic cholestasis of pregnancy[J]. Orphanet J Rare Dis, 2021, 16(1): 259.
[33] Ma Z, Liu Y, Chai L, et al. Metabolic changes in bile acids with pregnancy progression and their correlation with perinatal complications in intrahepatic cholestasis of pregnant patients[J]. Sci Rep, 2023, 13(1):1608.
[34] Li Y, Zhang X, Chen J, et al. Targeted metabolomics of sulfated bile acids in urine for the diagnosis and grading of intrahepatic cholestasis of pregnancy[J]. Genes Dis, 2018, 5(4):358-366.
[35] ACOG committee opinion no. 764: medically indicated late-preterm and early-term deliveries[J]. Obstet Gynecol, 2019, 133(2): e151-e155.
[36] Kong X, Kong Y, Zhang F Y, et al. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: a meta-analysis (a prisma-compliant study)[J]. Medicine (Baltimore), 2016, 95(40):e4949. Erratum in: Medicine (Baltimore), 2017, 96(3):e6031.
[37] Chappell L C, Bell J L, Smith A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial[J]. Lancet, 2019, 394(10201):849-860.
[38] Hagenbeck C, Pecks U, Lammert F, et al. Intrahepatic cholestasis of pregnancy[J]. Gynakologe, 2021,54(5):341-356.
[39] Roy A, Premkumar M, Mishra S, et al. Role of ursodeoxycholic acid on maternal serum bile acids and perinatal outcomes in intrahepatic cholestasis of pregnancy[J]. Eur J Gastroenterol Hepatol, 2021, 33(4):571-576.
[40] Keitel V, Dröge C, Häussinger D. Targeting FXR in Cholestasis[J]. Handb Exp Pharmacol, 2019, 256: 299-324.
[41] Anakk S, Watanabe M, Ochsner SA, et al. Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis[J]. J Clin Invest, 2022, 121(1):86-95.
[42] Krupa K, Hapshy V, Nguyen H, et al. Obeticholic Acid. 2022 Dec 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing,2022.
[43] Pataia V, McIlvride S, Papacleovoulou G, et al. Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 319(2): G197-G211.
[44] Lee R H, Mara G, Metz T D, et al. Society for maternal-fetal medicine consult series #53: intrahepatic cholestasis of pregnancy: replaces consult #13, April 2011[J]. Am J Obstet Gynecol, 2021, 224(2): B2-B9.
[45] Girling J, Knight C L, Chappell L, et al. Intrahepatic cholestasis of pregnancy: green-top guideline No. 43 June 2022[J]. BJOG, 2022, 129(13): e95-e114. |
